Literature DB >> 34148359

Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program.

Elvis A Akwo1,2,3, Cassianne Robinson-Cohen1,2,3, Cecilia P Chung4,3,5, Shailja C Shah6,3, Nancy J Brown7,8, T Alp Ikizler1,2,3, Otis D Wilson1,3, Bryce X Rowan9, Megan M Shuey10, Edward D Siew1,2,3, James M Luther7, Ayush Giri11,5, Jacklyn N Hellwege10, Digna R Velez Edwards11,12,13, Christianne L Roumie14, Ran Tao9,5, Phil S Tsao15,16,17, J Michael Gaziano18,19, Peter W F Wilson20,21, Christopher J O'Donnell19,22, Todd L Edwards13,23, Csaba P Kovesdy24,25, Adriana M Hung1,26,2,3.   

Abstract

[Figure: see text].

Entities:  

Keywords:  Treatment-resistant hypertension; apolipoprotein L1 variants; end-stage kidney disease; myocardial infarction; race; stroke

Mesh：

Substances：

Year:  2021        PMID： 34148359      PMCID： PMC8364328          DOI： 10.1161/HYPERTENSIONAHA.120.16181

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   9.897


  32 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

3.  Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Dawei Xie; Hsiang-Yu Chen; Amanda H Anderson; Lawrence J Appel; Shirisha Bodana; Carolyn S Brecklin; Paul Drawz; John M Flack; Edgar R Miller; Susan P Steigerwalt; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Mahboob Rahman
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

4.  Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.

Authors:  Esther de Beus; Michiel L Bots; Arjan D van Zuilen; Jack F M Wetzels; Peter J Blankestijn
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

5.  Association of APOL1 Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program.

Authors:  Alexander G Bick; Elvis Akwo; Cassianne Robinson-Cohen; Kyung Lee; Julie Lynch; Themistocles L Assimes; Scott DuVall; Todd Edwards; Huaying Fang; S Matthew Freiberg; Ayush Giri; Jennifer E Huffman; Jie Huang; Leland Hull; Rachel L Kember; Derek Klarin; Jennifer S Lee; Michael Levin; Donald R Miller; Pradeep Natarajan; Danish Saleheen; Qing Shao; Yan V Sun; Hua Tang; Otis Wilson; Kyong-Mi Chang; Kelly Cho; John Concato; J Michael Gaziano; Sekar Kathiresan; Christopher J O'Donnell; Daniel J Rader; Philip S Tsao; Peter W Wilson; Adriana M Hung; Scott M Damrauer
Journal:  Circulation       Date:  2019-07-24       Impact factor: 29.690

6.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

7.  Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.

Authors:  Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin
Journal:  Ann Intern Med       Date:  2012-11-06       Impact factor: 25.391

8.  Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.

Authors:  Christianne L Roumie; Edward Mitchel; Patricia S Gideon; Cristina Varas-Lorenzo; Jordi Castellsague; Marie R Griffin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-01       Impact factor: 2.890

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; Kristi Reynolds; David A Calhoun; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Kidney Int       Date:  2015-05-06       Impact factor: 10.612
View more
  1 in total

1.  Current apparent treatment-resistant hypertension in patients undergoing peritoneal dialysis: A multi-center cross-sectional study.

Authors:  Dan Li; Zhihao Huo; Danyang Liu; Nirong Gong; Fen Zhang; Yaozhong Kong; Yunfang Zhang; Xiaoyan Su; Qingdong Xu; Jiexia Feng; Fuzhang Luo; Cheng Wang; Xianrui Dou; Guohui Sun; Difei Zhang; Xianhui Qin; Guangqing Zhang; Fuhua Lu; Jun Ai
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-03-02       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.